Endocannabinoid and Psychological Responses to Yoga in Healthy Adults
- Conditions
- Healthy
- Interventions
- Behavioral: YogaBehavioral: Quiet Rest
- Registration Number
- NCT03710577
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 12
- greater than or equal to 18 years old and < 45 years old and
- report being healthy.
- Being pregnant or planning to become pregnant,
- currently smoking,
- having a history of light headedness or fainting during blood draws or physical activity,
- having a history of chest pain during physical activity,
- having a bone, joint, cardiac, or other medical condition that a doctor has said may be worsened by physical activity,
- taking medications for any chronic diseases such as high blood pressure or diabetes,
- responding 'Yes' to any of the seven questions on the Par-Q.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Yoga Yoga 40 minutes of Vinyasa yoga Quiet Rest Quiet Rest 40 minutes of quiet rest
- Primary Outcome Measures
Name Time Method Change in Plasma Concentration of N-arachidonoylethanolamine This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later) Plasma concentration of anandamide, one effector of the endocannabinoid system
Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG) This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later) Plasma concentration of 2-AG, one effector of the endocannabinoid system
- Secondary Outcome Measures
Name Time Method Change in Total Pain as Measured by the Short-form McGill Pain Questionnaire This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later) 15-item self-reported pain questionnaire that measures pain "right now." Scores range from 0-45 with higher scores indicating higher pain.
Change in Total Mood Disturbance as Measured by the Profile of Mood States This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later) 65-item self-reported mood questionnaire that measures mood "right now." Scores range from 0-200 with higher scores indicating higher mood disturbance.
Change in State Anxiety as Measured by the State-Trait Anxiety Inventory This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later) 20-item self-reported anxiety questionnaire that measures anxiety "right now." Scores range from 20-80 with higher scores indicating higher anxiety.
Trial Locations
- Locations (1)
University of Wisconsin-Madison Natatorium
🇺🇸Madison, Wisconsin, United States